Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three se... Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three segments: North America, Europe and International Markets. Each business segment manages a product portfolio in its region, including generics, which include biosimilars and over-the-counter products, as well as innovative medicines. 詳細を表示
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1Agreement builds on the proven and successful collaboration...
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG...
TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full...
Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent...
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinicsThe program, launching this month, will run for a minimum of three years PARSIPPANY...
Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which JKI will...
AJOVY® (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1Efficacy...
TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.2492 | 6.06113537118 | 20.61 | 22.1 | 20.41 | 9013546 | 21.67102826 | DR |
4 | -0.4108 | -1.84463403682 | 22.27 | 22.8 | 20.145 | 8644963 | 21.55732748 | DR |
12 | 3.5992 | 19.7108433735 | 18.26 | 22.8 | 16.15 | 9689328 | 19.28380344 | DR |
26 | 5.0792 | 30.2693682956 | 16.78 | 22.8 | 15.81 | 8324473 | 18.51046894 | DR |
52 | 10.7392 | 96.5755395683 | 11.12 | 22.8 | 11.08 | 9262184 | 16.29873451 | DR |
156 | 13.2592 | 154.176744186 | 8.6 | 22.8 | 6.7791 | 9916379 | 11.21784887 | DR |
260 | 11.6492 | 114.095984329 | 10.21 | 22.8 | 6.25 | 10254228 | 10.8015382 | DR |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約